Literature DB >> 29936556

Amyloid deposition and CBF patterns predict conversion of mild cognitive impairment to dementia.

Takayuki Kikukawa1, Takato Abe2, Suzuka Ataka1, Haruna Saito1, Itsuki Hasegawa1, Toshikazu Mino1, Jun Takeuchi1, Joji Kawabe3, Yasuhiro Wada4, Yasuyoshi Watanabe4, Yoshiaki Itoh1.   

Abstract

Mild cognitive impairment (MCI) can include the transition from a normal state to dementia. To explore biomarkers for the development of dementia, we performed an 18-month follow-up study in 28 patients with amnestic MCI. Amyloid deposition was examined using PiB PET, and cerebral blood flow (CBF) was examined using SPECT. Cognitive function was periodically assessed. The rate of conversion to dementia was higher in the PiB-positive/equivocal group (74%) than in the PiB-negative group (33%) (p = 0.041). Perfusion SPECT was performed in 16 patients. MCI patients with an AD-characteristic pattern of reduced CBF had a higher PiB-positive/equivocal rate (82%) than those with a non-AD pattern (20%) (p = 0.018), and patients with an AD pattern had a higher conversion rate (82%) than those with a non-AD pattern (40%) (p = 0.094). Clinically, all PiB-positive converters were diagnosed as having Alzheimer's disease (AD), whereas PiB-negative converters were thought to have some form of dementia other than AD. Amyloid PET is useful for predicting conversion to AD in MCI patients. A pattern analysis of perfusion SPECT findings might also be helpful for predicting conversion to AD, but with a lower specificity.

Entities:  

Keywords:  Alzheimer’s disease; Mild cognitive impairment; Perfusion SPECT; Pittsburg compound B; Positron emission tomography

Mesh:

Substances:

Year:  2018        PMID: 29936556     DOI: 10.1007/s10072-018-3477-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  22 in total

1.  SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study.

Authors:  W Jagust; R Thisted; M D Devous; R Van Heertum; H Mayberg; K Jobst; A D Smith; N Borys
Journal:  Neurology       Date:  2001-04-10       Impact factor: 9.910

2.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.

Authors:  William J Jagust; Dan Bandy; Kewei Chen; Norman L Foster; Susan M Landau; Chester A Mathis; Julie C Price; Eric M Reiman; Daniel Skovronsky; Robert A Koeppe
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

3.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

4.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Authors:  William E Klunk; Chester A Mathis; Julie C Price; Brian J Lopresti; Steven T DeKosky
Journal:  Brain       Date:  2006-11       Impact factor: 13.501

5.  Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline.

Authors:  P A Boyle; R S Wilson; N T Aggarwal; Y Tang; D A Bennett
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

Review 6.  Current concepts in mild cognitive impairment.

Authors:  R C Petersen; R Doody; A Kurz; R C Mohs; J C Morris; P V Rabins; K Ritchie; M Rossor; L Thal; B Winblad
Journal:  Arch Neurol       Date:  2001-12

7.  Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.

Authors:  J Koivunen; N Scheinin; J R Virta; S Aalto; T Vahlberg; K Någren; S Helin; R Parkkola; M Viitanen; J O Rinne
Journal:  Neurology       Date:  2011-02-16       Impact factor: 9.910

8.  Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

Authors:  A Okello; J Koivunen; P Edison; H A Archer; F E Turkheimer; K Någren; R Bullock; Z Walker; A Kennedy; N C Fox; M N Rossor; J O Rinne; D J Brooks
Journal:  Neurology       Date:  2009-07-08       Impact factor: 9.910

Review 9.  A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review.

Authors:  Christopher M Davison; John T O'Brien
Journal:  Int J Geriatr Psychiatry       Date:  2013-10-09       Impact factor: 3.485

10.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Authors:  Milos D Ikonomovic; William E Klunk; Eric E Abrahamson; Chester A Mathis; Julie C Price; Nicholas D Tsopelas; Brian J Lopresti; Scott Ziolko; Wenzhu Bi; William R Paljug; Manik L Debnath; Caroline E Hope; Barbara A Isanski; Ronald L Hamilton; Steven T DeKosky
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

View more
  5 in total

1.  Brain Perfusion Single-Photon Emission Computed Tomography Using an Easy Z-Score Imaging System Predicts Progression to Neurodegenerative Dementia in Rapid Eye Movement Sleep Behavior Disorder.

Authors:  Kyoko Numahata; Tomoyuki Miyamoto; Yasuhisa Akaiwa; Masayuki Miyamoto
Journal:  Dement Geriatr Cogn Disord       Date:  2022-01-31       Impact factor: 3.346

2.  Efficacy and Limitations of rCBF-SPECT in the Diagnosis of Alzheimer's Disease With Amyloid-PET.

Authors:  Miwako Takahashi; Tomoko Tada; Tomomi Nakamura; Keitaro Koyama; Toshimitsu Momose
Journal:  Am J Alzheimers Dis Other Demen       Date:  2019-04-09       Impact factor: 2.035

3.  Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease.

Authors:  Kazuhiro Kitajima; Kazuo Abe; Masanaka Takeda; Hiroo Yoshikawa; Mana Ohigashi; Keiko Osugi; Hidenori Koyama; Koichiro Yamakado
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

4.  Genetic Deficiency of MicroRNA-15a/16-1 Confers Resistance to Neuropathological Damage and Cognitive Dysfunction in Experimental Vascular Cognitive Impairment and Dementia.

Authors:  Chao Zhou; Ping Sun; Yang Xu; Yuang Chen; Yixian Huang; Milton H Hamblin; Lesley Foley; T Kevin Hitchens; Song Li; Ke-Jie Yin
Journal:  Adv Sci (Weinh)       Date:  2022-04-11       Impact factor: 17.521

5.  Characteristics of Regional Cerebral Blood Flow in Alzheimer Disease and Amnestic Mild Cognitive Impairment by Single-Photon Emission Computerized Tomography: A Cross-Sectional Study.

Authors:  Yota Kunieda; Chiaki Arakawa; Takumi Yamada; Mizue Suzuki; Shingo Koyama; Yosuke Kimura; Takeo Ichikawa; Shuhei Shino; Minoru Yamada; Ryuto Hirokawa; Tadamitsu Matsuda; Tomokazu Takakura; Tomohide Adachi; Haruhiko Hoshino
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2021-05-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.